Allotex
PrivateLast Round
Series B
Extension
Nov 30, 2023
Total Funding Raised
$46.7M
Momentum Score
25 /100
Company Overview
Allotex is an ophthalmic biotechnology company specializing in innovative treatments for presbyopia, hyperopia, and myopia through the use of precisely-shaped human corneal allografts and a compact excimer laser system to create permanent, living contact lenses or lens inserts.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Allotex Comps
Public and private peers based on sector, stage, and business model.
Allotex Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Nov 30, 2023 | ||||
| Series B | Jul 9, 2023 | ||||
| Series B | Feb 1, 2018 |
Allotex Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| KCK MedTech | Series B Extension, Series B |
| Junson Capital | Series B, Series B Extension |
| Supernova Invest | Series B Extension, Series B |
| Exor | Series B |
| Exor Ventures | Series B Extension, Series B |
Allotex Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Allotex's valuation, stock price, and market status.
